Education
About Us
Working with TipRanks
Follow Us
AC Immune (DE:IMR)
:IMR
IMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.06 - €4.73
Previous CloseN/A
Volume0.00
Average Volume (3M)501.00
Market Cap
€220.72M
Enterprise Value€197.72M
Total Cash (Recent Filing)CHF57.01M
Total Debt (Recent Filing)CHF3.33M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Mar 25, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding99,680,405
10 Day Avg. Volume840
30 Day Avg. Volume501
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.69
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.62Price Target Upside220.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
AC Immune SA News
PremiumCompany Announcements
AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership
PremiumCompany Announcements
AC Immune Announces Promising Safety Data for Down Syndrome Therapy
PremiumCompany Announcements
AC Immune Q3 2024: Strong Progress and Financial Turnaround
PremiumCompany Announcements
AC Immune’s Promising Trial Results for Parkinson’s Therapy---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAC Immune announced positive interim results for ACI-7104, demonstrating strong immunogenicity results after only 3 months of treatment and favorable safety results.
PartnershipsThe broad relationship with Takeda for the ACI-24 vaccine presents potential for clearing Aβ oligomers.
Bears Say
Biology RiskThere is still some biology risk to the program as no therapeutic targeting α-Syn has been approved.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.19% Mutual Funds
1.03% Other Institutional Investors
97.24% Public Companies and Individual Investors
IMR FAQ
What was AC Immune’s price range in the past 12 months?
AC Immune lowest stock price was €2.06 and its highest was €4.73 in the past 12 months.
What is AC Immune’s market cap?
AC Immune’s market cap is €220.72M.
When is AC Immune’s upcoming earnings report date?
AC Immune’s upcoming earnings report date is Mar 25, 2025 which is in 17 days.
How were AC Immune’s earnings last quarter?
AC Immune released its earnings results on Nov 05, 2024. The company reported €0.053 earnings per share for the quarter, beating the consensus estimate of -€0.145 by €0.198.
Is AC Immune overvalued?
According to Wall Street analysts AC Immune’s price is currently Undervalued.
Does AC Immune pay dividends?
AC Immune does not currently pay dividends.
What is AC Immune’s EPS estimate?
AC Immune’s EPS estimate is -0.2.
How many shares outstanding does AC Immune have?
AC Immune has 99,680,405 shares outstanding.
What happened to AC Immune’s price movement after its last earnings report?
AC Immune reported an EPS of €0.053 in its last earnings report, beating expectations of -€0.145. Following the earnings report the stock price went up 3.738%.
Which hedge fund is a major shareholder of AC Immune?
Currently, no hedge funds are holding shares in DE:IMR
---
AC Immune SA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.62 (220.20% Upside)
€7.62 (220.20% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.43%
12-Months-Change
Fundamentals
Return on Equity
-30.57%
Trailing 12-Months
Asset Growth
85.25%
Trailing 12-Months
Company Description
AC Immune
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
---
IMR Stock 12 Month Forecast
Average Price Target
€7.62
▲(220.20% Upside)
Technical Analysis
Cassava Sciences
―
Prothena
―
Anavex Life Sciences
―
Axsome Therapeutics
―
Annovis Bio
―
Best Analysts Covering IMR
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+1.48%
reiterated a buy rating 4 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +1.48% per trade.
---